以下文章来源于中国企业家杂志 ，作者胡楠楠 中国企业家杂志 . 讲好企业家故事，弘扬企业家精神 作者： 胡楠楠 来源：中国企业家杂志 钟睒睒又加码了新生意。 近期，据浙江省人民政府官网，农夫山泉计划投资 2842万元，扩建杭州建德新安江饮品有限公司年产7000吨的食用冰项目。据了解，该项目拟利 用新安江街道朱家埠厂区现有闲置生产车间，购置国内外领先的流水方冰生产线1条，高透冰制冰生产线1条，主要用来生产食用冰。 这两年，冰杯成为了夏日水饮新单品，也成为食品饮料行业高速增长的细分品类。《 2025中国都市消费行为白皮书》显示， 冰杯品类的销量已连 续两年保持 300%以上的增速。 据首创证券研报，冰杯是一种以透明塑料杯封装食用冰块的即时冷却容器，主要用于消费者自制冷饮，分为纯水冰杯和风味冰杯。 2024年以来， 冰杯在年轻人群中流行。因其满足了夏日即时解渴降温需求，与酒或饮料的组合搭配，也增加了口味探索及个性表达的属性，万物皆可"冰杯 +"——DIY冰品酒饮成为了年轻人群的一种线上社交潮流。《中国企业家》注意到，不少网友在社交平台上分享用冰杯自制饮品的笔记。 农夫山泉创始人钟睒睒自然不会错过这个高速增长的品类。 ...

Core Insights - The company reported a revenue of 801 million yuan for the first three quarters of 2025, representing a year-over-year increase of 8.6%, while the net profit attributable to shareholders was 243 million yuan, down 21.5% year-over-year [1] - The third quarter of 2025 saw a revenue of 285 million yuan, up 12.9% year-over-year and 3.7% quarter-over-quarter, with a net profit of 97 million yuan, reflecting a year-over-year increase of 3.73% and a quarter-over-quarter increase of 17.3% [1] - The gross margin faced pressure, decreasing to 47.7%, down 6.9 percentage points year-over-year, attributed to product structure transformation and high costs during the ramp-up phase of subsidiaries [1] Financial Performance - The operating expense ratio increased to 24.6%, up 6.8 percentage points year-over-year, with R&D expense ratio at 13.1%, an increase of 5.3 percentage points [2] - Operating cash flow for the first three quarters was 251 million yuan, a significant increase of 60.6% year-over-year [2] - Contract liabilities rose to 32 million yuan, a 60.5% increase from the beginning of the year, indicating a substantial increase in orders [2] Business Development - The company is diversifying its product offerings, with significant growth in special functional materials and aerospace components, and several new products in the trial production phase [2][4] - Subsidiaries are showing rapid growth, with Huayin Hangfa achieving a revenue of 103 million yuan, up 143% year-over-year, and signing contracts worth approximately 244 million yuan [2][3] - Huayin Guangsheng reported a revenue of 10 million yuan, up 184.9% year-over-year, with a strong order backlog [3] Capacity Expansion - The company is accelerating the construction of its main and subsidiary projects, with production capacity gradually ramping up [4] - The Huayin Hangfa project is nearing full production by the end of 2025, while the second phase of the Ruihua Sheng project is expected to enhance capacity by the end of 2025 [4] Investment Outlook - The company is focusing on a diversified product layout, covering five main business areas, which is expected to enhance business scale as products transition to mass production [4] - Projected net profits for 2025-2027 are estimated at 401 million, 535 million, and 729 million yuan, with corresponding EPS of 1.47, 1.96, and 2.68 yuan, indicating a favorable investment outlook [4]

Core Viewpoint - Dong'e Ejiao is experiencing a decline in market confidence despite reporting revenue and profit growth, indicating deeper concerns about its business model and reliance on core products [2][3][8]. Financial Performance - Dong'e Ejiao reported a revenue of 28.45 billion yuan in the first half of 2025, with its core products contributing 93.24% to total revenue, an increase from 91.5% in 2022 [9][10]. - The company announced a cash dividend of 12.69 yuan per 10 shares, totaling approximately 8.17 billion yuan, which accounted for 99.94% of its net profit for the first half of 2025 [7][8]. - Despite the high dividend payout, the stock price fell from around 60 yuan per share in April 2025 to 47.38 yuan by October 10, 2025, marking a cumulative decline of 20.91% [4][5]. Market Dynamics - The Wind Pharmaceutical and Biological Index increased by 25.8% during the same period, contrasting sharply with Dong'e Ejiao's stock performance [5]. - The company faces significant competition from rivals like Fupai Ejiao and Tongrentang, which is impacting its market share [12][23]. Product Dependency and Innovation - Dong'e Ejiao's heavy reliance on its core product, Ejiao, raises concerns about its risk management capabilities, as over 80% of its revenue comes from Ejiao blocks and compound Ejiao syrup [9][10]. - The company has not successfully developed new growth drivers, with new products like "Royal Weichang 1619" and "Zhuangben" still in the incubation stage and projected to generate less than 10 million yuan in sales in 2024 [9][10]. Cost and Pricing Pressures - The gross margin for Ejiao and related products decreased to 74.83% in the first half of 2025, marking the first decline since 2023, primarily due to competitive and cost pressures [10][11]. - The price of donkey hides, a key raw material for Ejiao, has surged over 50% this year, exacerbating cost challenges for the company [13][15]. Inventory and Receivables - Dong'e Ejiao's inventory stood at 920 million yuan, with an increased turnover period of 198 days, indicating slower inventory movement [19]. - Accounts receivable surged by 583.32% in the first quarter of 2025, raising concerns about potential demand weakness and channel inventory issues [20][22]. Industry Trends - The overall market for Ejiao has contracted from 350 billion yuan in 2018 to 280 billion yuan in 2023, driven by high prices and doubts about product efficacy [23].